Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer

Cancer Science

Volumn 98, Issue 6, 2007, Pages 874-881

  Nakamura, Takafumi ^a   Shima, Tomoko ^a   Saeki, Ai ^a   Hidaka, Takao ^a   Nakashima, Akitoshi ^a   Takikawa, Osamu ^b   Saito, Shigeru ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CANCER CELL; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENDOMETRIUM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY T LYMPHOCYTE; UTERINE CERVIX CANCER; UTERUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; DISEASE PROGRESSION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; T-LYMPHOCYTES, REGULATORY; UTERINE CERVICAL NEOPLASMS;

EID: 34247862322     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00470.x     Document Type: Article

References (40)

1. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380-4.
2. Gerloni M, Zanetti M. CD4 T cells in tumor immunity. Springer Semin Immunopathol 2005; 27: 37-48.
3. Uyttenhove C, Pilotte L, Theate I et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9: 1269-74.
4. Friberg M, Jennings R, Alsarraj M et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 2002; 101: 151-5.
5. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 11: 312-19.
6. Mellor AL, Munn DH. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762-74.
7. Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-3.
8. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189: 1363-72.
9. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002; 196: 459-68.
10. Sedlmayr P, Semlitsch M, Gebru G et al. Expression of indoleamine 2,3-dioxygenase in carcinoma of human endometrium and uterine cervix. Adv Exp Med Biol 2003; 527: 91-5.
11. + regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 18-32.
12. + regulatory T cells and their ligands: Implications for immunotherapy. Immunity 2004; 20: 107-18.
13. Karim M, Bushell AR, Wood KJ. Regulatory T cells in transplantation. Curr Opin Immunol 2002; 14: 584-91.
14. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685-711.
15. Munn DH, Sharma MD, Hou D et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004; 114: 280-90.
16. Mellor AL, Baban B, Chandler P et al. Cutting edge: Induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2003; 171: 1652-5.
17. + regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003; 198: 235-47.
18. + regulatory T cells in normal and tumor-bearing mice. Int Immunopharmacol 2004; 4: 1785-93.
19. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 18 538-43.
20. Lan RY, Cheng C, Lian ZX et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology 2006; 43: 729-37.
21. Takikawa O, Kuroiwa T, Yamazaki F, Kido R. Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J Biol Chem 1988; 263: 2041-8.
22. Perez L, Shurin MR, Collins B, Kogan D, Tourkova IL, Shurin GV. Comparative analysis of CD1a, S-100, CD83, and CD11c human dendritic cells in normal, premalignant, and malignant tissues. Histol Histopathol 2005; 20: 1165-72.
23. Kumada T, Tsuneyama K, Hatta H, Ishizawa S, Takano Y. Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital. Mod Pathol 2004; 17: 1141-9.
24. +CD25 high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245-53.
25. + regulatory T cells. Nat Immunol 2003; 4: 330-6.
26. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-61.
27. Wolf D, Wolf AM, Rumpold H et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005; 11: 8326-31.
28. Lee JR, Dalton RR, Messina JL et al. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Laboratory Invest 2003; 83: 1457-66.
29. Munn DH. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 2006; 18: 220-5.
30. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-9.
31. Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115: 3623-33.
32. Yamada H, Odonnell MA, Matsumoto T, Luo Y. Interferon-gamma up-regulates toll-like receptor 4 and cooperates with lipopolysaccharide to produce macrophage-derived chemokine and interferon-gamma inducible protein-10 in human bladder cancer cell line RT4. J Urol 2005; 174: 1119-23.
33. Grohmann U, Orabona C, Fallarino F et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097-101.
34. Miwa N, Hayakawa S, Miyazaki S et al. IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon-gamma increase in normal pregnancy but decrease in spontaneous abortion. Mol Hum Reprod 2005; 11: 865-70.
35. Fallarino F, Grohmann U, Hwang KW et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003; 4: 1206-12.
36. Brandacher G, Perathoner A, Ladurner R et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: Effect on tumor-infiltrating T cells. Clin Cancer Res 2006; 12: 1144-51.
37. Okamoto A, Nikaido T, Ochiai K et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 2005; 11: 6030-9.
38. Alvaro T, Lejeune M, Salvado MT et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005; 11: 1467-73.
39. + T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006; 12: 465-72.
40. Ishio T, Goto S, Tahara K, Tone S, Kawano K, Kitano S. Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J Gastroenterol Hepatol 2004; 19: 319-26.